학술논문

QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2017, 28 1p. Supplement: 5
Subject
Language
English
ISSN
15698041